创新药研发数量超1250种，中国药企超欧赶美！

Core Viewpoint - The rapid advancement of China's biotechnology sector is comparable to its breakthroughs in artificial intelligence and electric vehicles, with Chinese pharmaceutical companies now challenging Western dominance in innovation [1][2]. Group 1: Growth in Drug Development - In the past year, over 1250 new drugs entered the research and development phase in China, significantly surpassing the EU and nearing the US's 1440 new drugs [1]. - China's contribution to global innovative drug development has increased from 160 compounds in 2015 to nearly equal levels with the US, indicating a strong growth trajectory [2]. - The number of innovative drugs entering the R&D pipeline in China is expected to surpass that of the US in the coming years [2]. Group 2: Quality of Innovation - Chinese biotech innovation quality has improved, gaining recognition from global regulatory bodies like the FDA and EMA, which are now prioritizing the review of Chinese drugs [5]. - As of 2024, China has slightly outpaced the EU in obtaining fast-track review qualifications for new drugs, enhancing its competitive edge [5]. - A notable example of innovation is a cell therapy developed by Legend Biotech, which has received multiple fast-track designations and is considered superior to a similar US therapy [5]. Group 3: Market Dynamics and Acquisitions - Major pharmaceutical companies are increasingly acquiring Chinese biotech firms, indicating a shift in the competitive landscape towards China [6][9]. - Akeso's new cancer drug has shown higher efficacy than Merck's Keytruda, attracting significant global attention and leading to record acquisition deals [9]. - The frequency and value of transactions involving Chinese drug candidates are rising, reflecting confidence in their international competitiveness [9]. Group 4: Cost and Efficiency Advantages - Chinese biotech companies can conduct research at lower costs and faster speeds across all R&D stages, aided by a large patient base and centralized hospital networks [11]. - The efficiency of Chinese doctors in patient recruitment for clinical trials is notably higher, taking only half the time compared to their US counterparts [11]. - Since 2021, China has become the preferred location for clinical trials, initiating the highest number of new studies globally [13]. Group 5: Future Outlook and Geopolitical Context - The rapid development of China's biotech ecosystem raises concerns among US policymakers about losing leadership in a critical industry [14][15]. - The US government is responding by tightening controls on scientific equipment exports and promoting domestic biotech growth [15]. - Despite geopolitical tensions, Chinese companies are focused on expanding into developed Western markets to benefit global patients [15].